Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

NCT06122896 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT06122896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06122896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Recruiting
Start date
November 21, 2023
Completion date
October 31, 2041
Enrollment
5,000 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic ductal adenocarcinoma, pancreatic neoplasm, pdac, pdac - pancreatic ductal adenocarcinoma